These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 4156144)

  • 21. Autonomic nervous system activity and psychiatric severity in schizophrenia.
    Fujibayashi M; Matsumoto T; Kishida I; Kimura T; Ishii C; Ishii N; Moritani T
    Psychiatry Clin Neurosci; 2009 Aug; 63(4):538-45. PubMed ID: 19496998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subnormal CSF levels of neurotensin in a subgroup of schizophrenic patients: normalization after neuroleptic treatment.
    Widerlöv E; Lindström LH; Besev G; Manberg PJ; Nemeroff CB; Breese GR; Kizer JS; Prange AJ
    Am J Psychiatry; 1982 Sep; 139(9):1122-6. PubMed ID: 6126127
    [No Abstract]   [Full Text] [Related]  

  • 23. The relationship of the brief psychiatric rating scale to neuropsychological deficits in phenothiazine-treated schizophrenics.
    Golden CJ; Carpenter B; Wilkening G; Ruedrich S; Chu CC; Graber B
    Psychopharmacol Bull; 1983; 19(3):513-7. PubMed ID: 6138799
    [No Abstract]   [Full Text] [Related]  

  • 24. [The factors influencing the effectiveness of therapy in schizophrenia and the principles of patient selection for a comparative evaluation of the results of treatment (a survey of the literature)].
    Karimov RK
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(4):612-9. PubMed ID: 4574524
    [No Abstract]   [Full Text] [Related]  

  • 25. [Mortality among chronic schizophrenic patients: a prospective 14-year follow-up study of 150 schizophrenic patients].
    Loas G; Azi A; Noisette C; Yon V
    Encephale; 2008 Jan; 34(1):54-60. PubMed ID: 18514151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of Tybamate in chronic schizophrenia. (Minor tranquilizers as adjunct therapy in psychosis).
    Serafetinides EA; Clark ML
    Dis Nerv Syst; 1971 Aug; 32(8):567-71. PubMed ID: 5094163
    [No Abstract]   [Full Text] [Related]  

  • 27. Psychophysiological patterns of response in schizophrenia.
    Thetford PE; Spohn HE; Everds JP
    J Nerv Ment Dis; 1974 Feb; 158(2):104-14. PubMed ID: 4149886
    [No Abstract]   [Full Text] [Related]  

  • 28. Pimozide (orap, R 6238) in residual schizophrenia. A clinical evaluation with long-term double-blind follow-up.
    Denijs EL; Vereecken JL
    Psychiatr Neurol Neurochir; 1973; 76(1):47-59. PubMed ID: 4699105
    [No Abstract]   [Full Text] [Related]  

  • 29. A blind comparison of clozapine and perphenazine in schizophrenics.
    Rodová A; Svestka J; Náhunek K; Cesková E
    Act Nerv Super (Praha); 1973 May; 15(2):94-5. PubMed ID: 4752682
    [No Abstract]   [Full Text] [Related]  

  • 30. Do patients with paranoid and disorganized schizophrenia respond differently to antipsychotic drugs?
    Corves C; Engel RR; Davis J; Leucht S
    Acta Psychiatr Scand; 2014 Jul; 130(1):40-5. PubMed ID: 24299424
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Discriminative study of the effect of a psychotropic drug by use of B.P.R.S. cards].
    Sizaret P; Degiovanni A; Penaud J
    Encephale; 1972; 61(4):316-24. PubMed ID: 4145384
    [No Abstract]   [Full Text] [Related]  

  • 32. Optimizing early prediction for antipsychotic response in schizophrenia.
    Chang YC; Lane HY; Yang KH; Huang CL
    J Clin Psychopharmacol; 2006 Dec; 26(6):554-9. PubMed ID: 17110810
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fluspirilene, a long-acting injectable neuroleptic.
    Ciccarelli G; Nosé F; Zuanazzi GF
    Acta Psychiatr Belg; 1972 Nov; 72(6):736-47. PubMed ID: 4679675
    [No Abstract]   [Full Text] [Related]  

  • 34. Socio-demographic and clinical profiles of paranoid and nonparanoid schizophrenia: a prospective, multicenter study in China.
    Xiang YT; Wang CY; Chiu HF; Weng YZ; Bo QJ; Chan SS; Lee EH; Ungvari GS
    Perspect Psychiatr Care; 2011 Jul; 47(3):126-30. PubMed ID: 21707627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Violence among schizophrenia out-patients compliant with medication: prevalence and associated factors.
    Bobes J; Fillat O; Arango C
    Acta Psychiatr Scand; 2009 Mar; 119(3):218-25. PubMed ID: 19178395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Time relationship between the appearance of persisting extrapyramidal hyperkineses and psychotic recurrences following sudden interruption of prolonged neuroleptic therapy of chronic schizophrenic patients].
    Degkwitz R; Bauer MP; Gruber M; Hampel G; Luxenburger O; Richartz M; Wenzel W
    Arzneimittelforschung; 1970 Jul; 20(7):890-3. PubMed ID: 4918918
    [No Abstract]   [Full Text] [Related]  

  • 37. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW; Gueorguieva RV; Baker CB; Makuch RW
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Arguments for early treatment of refractory schizophrenia].
    Lombertie ER; Salome N; Villegier P; Laghrissi-Thode F; Nassif F
    Encephale; 1995 Jun; 21 Spec No 3():29-33. PubMed ID: 7628338
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Action of flupentixol decanoate in chronic psychoses of the schizophrenic type].
    Evrard E; Heusghem C; Molders V; Plomteux G; Lebas A
    Acta Psychiatr Belg; 1972 Sep; 72(5):573-94. PubMed ID: 4669430
    [No Abstract]   [Full Text] [Related]  

  • 40. An open study with a new long-acting neuroleptic.
    Fleischhauer J; Angst J; Padrutt A; Vetter P
    Act Nerv Super (Praha); 1973 May; 15(2):85-6. PubMed ID: 4752678
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.